COVID-19 vaccines Vaccine safety data Main navigation COVID-19 vaccines Pfizer LP.8.1 COVID-19 vaccine safety data – all participants Pfizer JN.1 COVID-19 vaccine safety data – all participants Pfizer XBB.1.5 COVID-19 vaccine Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Moderna XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab Vaccine safety in Australia AusVaxSafety summary reports AusVaxSafety is conducting active vaccine safety surveillance of the COVID-19 vaccines in use in Australia to ensure their ongoing safety.Latest monthly COVID-19 vaccine safety dataClick on the tiles below to view AusVaxSafety COVID-19 vaccine safety data for specific population groups. Pfizer LP.8.1 COVID-19 vaccine safety data – all participants View the latest Pfizer LP.8.1 COVID-19 vaccine safety data here Pfizer JN.1 COVID-19 vaccine safety data – all participants View the latest Pfizer JN.1 COVID-19 vaccine safety data here Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccine safety data – all participants View the latest Pfizer XBB.1.5 COVID-19 vaccine safety data here Pfizer paediatric (5–11 years) COVID-19 vaccine safety data – child participants View the latest Pfizer paediatric (5–11 years) COVID-19 vaccine safety data here Moderna monovalent Omicron XBB.1.5 COVID-19 vaccine safety data – all participants View the latest Moderna XBB.1.5 COVID-19 vaccine safety data here Pfizer bivalent BA.4/5- COVID-19 vaccine View the latest Pfizer bivalent BA.4/5 COVID-19 vaccine safety data here Moderna bivalent COVID-19 vaccine View the latest Moderna bivalent COVID-19 vaccine safety data here Pfizer bivalent BA.1 COVID-19 vaccine View the latest Pfizer bivalent BA.1 COVID-19 vaccine safety data here Pfizer COVID-19 vaccine adult formulation View the latest safety data for Pfizer COVID-19 vaccine adult formulation here Moderna COVID-19 vaccine View the latest Moderna COVID-19 vaccine safety data here Novavax COVID-19 vaccine View the latest Novavax COVID-19 vaccine safety data here AstraZeneca COVID-19 vaccine View the latest AstraZeneca COVID-19 vaccine safety data here Vaccine safety data Main navigation COVID-19 vaccines Pfizer LP.8.1 COVID-19 vaccine safety data – all participants Pfizer JN.1 COVID-19 vaccine safety data – all participants Pfizer XBB.1.5 COVID-19 vaccine Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Moderna XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab Vaccine safety in Australia AusVaxSafety summary reports News & events All news & events 21 May 2026 | News Australia’s first real-world safety data confirm nasal spray influenza vaccine is well-tolerated by children and adolescents 02 April 2026 | News AusVaxSafety begins surveillance of 2026 influenza vaccines, including new nasal spray option 05 March 2026 | News New LP.8.1 COVID-19 vaccines well tolerated, new AusVaxSafety data show 14 July 2025 | News Fewer adverse events reported following NIP pneumococcal vaccine change